Biogen shares could be attractive for longer term investors, says Leerink

theflyonthewall.com

Leerink predicts that Biogen's stock could perform well in 2013, driven by strong performances by its MS and hemophilia treatments. The firm reiterates its $158-$167 valuation and Outperform rating on the stock.

View Comments